Literature DB >> 23399321

MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation.

Shuai Li1, Huimin Meng, Feng Zhou, Lili Zhai, Lina Zhang, Feng Gu, Yu Fan, Ronggang Lang, Li Fu, Lin Gu, Liqiang Qi.   

Abstract

Ductal carcinoma in situ (DCIS) is the most common type of non-invasive breast cancer. The currently accepted step-wise model suggests that breast cancer progressed in the following manner: normal breast cell→usually ductal hyperplasia (UDH)→atypical ductal hyperplasia (ADH)→DCIS→invasive ductal carcinoma (IDC). Therefore, DCIS can serve as a good model to analyze the mechanism underlying invasive breast cancer occurrence. MicroRNAs (miRNAs) are a novel class of small non-coding RNAs (~22nt) involved in the regulation of various biological processes. Altered miRNA expression could also contribute to the origination of cancer, including breast cancer. Here, by using miRNA microarray and real time PCR, we analyzed the miRNA expression profile in 21 DCIS and the corresponding normal tissues. miR-10b, miR-125b, miR-132, miR-145, miR-154-3p, miR-382-5p and miR-409-3p were found to be significantly deregulated in DCIS. Results from CCK-8 assay showed that the overexpression of miR-132 could inhibit the proliferation of breast cancer cell line. High expression of miR-132 could also inhibit the colony formation. Our findings will lead to further understanding of the development of breast cancer.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23399321     DOI: 10.1016/j.prp.2012.12.002

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  34 in total

1.  Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma.

Authors:  Jie Yang; Tiantian Gao; Jie Tang; Haikang Cai; Lijun Lin; Shiping Fu
Journal:  Mol Cell Biochem       Date:  2013-06-26       Impact factor: 3.396

2.  miR-132 inhibits colorectal cancer invasion and metastasis via directly targeting ZEB2.

Authors:  Yong-Bin Zheng; Hai-Ping Luo; Qiang Shi; Zhi-Nan Hao; Yu Ding; Qiu-Shuang Wang; Sheng-Bo Li; Gao-Chun Xiao; Shi-Lun Tong
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

3.  Serum expression levels of microRNA-382-3p, -598-3p, -1246 and -184 in breast cancer patients.

Authors:  Lun Fu; Zhaoyun Li; Jie Zhu; Pan Wang; Guangmin Fan; Yuechu Dai; Zhibao Zheng; Yang Liu
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

4.  miR-132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells.

Authors:  Jin Wang; Guoxing Xu; Feng Shen; Yifan Kang
Journal:  Tumour Biol       Date:  2014-01-22

5.  The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p.

Authors:  Yinting Chen; Linjuan Zeng; Yong Wang; William H Tolleson; Bridgett Knox; Si Chen; Zhen Ren; Lei Guo; Nan Mei; Feng Qian; Kaihong Huang; David Liu; Weida Tong; Dianke Yu; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2017-08-16       Impact factor: 5.858

6.  Human thymic stromal lymphopoietin promotes the proliferation and invasion of cervical cancer cells by downregulating microRNA-132 expression.

Authors:  Wen-Jie Zhou; Hui-Li Yang; Kai-Kai Chang; Yi Meng; Ming-Yan Wang; Min-Min Yuan; Ming-Qing Li; Feng Xie
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

7.  MicroRNA-132 enhances transition from inflammation to proliferation during wound healing.

Authors:  Dongqing Li; Aoxue Wang; Xi Liu; Florian Meisgen; Jacob Grünler; Ileana R Botusan; Sampath Narayanan; Erdem Erikci; Xi Li; Lennart Blomqvist; Lei Du; Andor Pivarcsi; Enikö Sonkoly; Kamal Chowdhury; Sergiu-Bogdan Catrina; Mona Ståhle; Ning Xu Landén
Journal:  J Clin Invest       Date:  2015-06-29       Impact factor: 14.808

8.  miR-132/212 cluster inhibits the growth of lung cancer xenografts in nude mice.

Authors:  Judong Luo; Cuicui Meng; Yiting Tang; Shuyu Zhang; Meizhen Wan; Yanzhi Bi; Xifa Zhou
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 9.  Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.

Authors:  Bethany N Hannafon; Wei-Qun Ding
Journal:  Am J Pathol       Date:  2018-09-29       Impact factor: 4.307

10.  microRNAs and Prostate Cancer.

Authors:  Sajni Josson; Leland W K Chung; Murali Gururajan
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.